1. The purpose of this study is to evaluate the safety and feasibility of transcranial ultrasound stimulation (TUS) treatment in patients with schizophrenia. Subjects are individuals diagnosed with schizophrenia who will receive non-invasive, low-intensity pulsed ultrasound stimulation targeting the hippocampus and its surrounding regions. Evaluations will be conducted before and after the treatment sessions, including electrocardiograms (ECG), blood biochemistry tests, psychiatric symptom assessments, depression level assessments, and cognitive function assessments. 2. The primary objective is to assess the safety of this intervention in patients with schizophrenia. The secondary objective is to explore whether the current stimulation parameters may lead to improvements in the assessed symptoms. Ultimately, this study aims to support the future application of low-intensity pulsed ultrasound as a potential intervention to alleviate symptoms of schizophrenia and improve patients' quality of daily life.
Age range
18 Years – 65 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Change from Screening phase (4 weeks before the initiation of treatment) in serum concentrations of BDNF at 5(+4) Weeks.
Timeframe: Screening phase (4 weeks before the initiation of treatment) and Week 5(+4 weeks)
Change from Screening phase (4 weeks before the initiation of treatment) in serum concentrations of IL-1 at 5(+4) Weeks.
Timeframe: Screening phase (4 weeks before the initiation of treatment) and Week 5(+4 weeks)
Change from Screening phase (4 weeks before the initiation of treatment) in serum concentrations of IL-6 at 5(+4) Weeks.
Timeframe: Screening phase (4 weeks before the initiation of treatment) and Week 5(+4 weeks)
Change from Screening phase (4 weeks before the initiation of treatment) in serum concentrations of IL-8 at 5(+4) Weeks.
Timeframe: Screening phase (4 weeks before the initiation of treatment) and Week 5(+4 weeks)
Change from Screening phase (4 weeks before the initiation of treatment) in serum concentrations of TNF-alpha at 5(+4) Weeks.
Timeframe: Screening phase (4 weeks before the initiation of treatment) and Week 5(+4 weeks)
Status of neurological examination
Timeframe: baseline establishment, and Week 5(+4 weeks)
Height in centimeters
Timeframe: Screening phase (4 weeks before the initiation of treatment), and Week 5(+4 weeks)
Weight in kilograms
Timeframe: Screening phase (4 weeks before the initiation of treatment) and Week 5(+4 weeks)
Temperature in Celsius
Timeframe: Screening phase (4 weeks before the initiation of treatment) and Week 5(+4 weeks)
Respiratory rate in breaths per minutes
Timeframe: Screening phase (4 weeks before the initiation of treatment) and Week 5(+4 weeks)
Blood pressure in mmHg
Timeframe: Screening phase (4 weeks before the initiation of treatment) and Week 5(+4 weeks)
Electrocardiogram (ECG) R-R interval
Timeframe: Screening phase (4 weeks before the initiation of treatment) and Week 5(+4 weeks)